Sarcoma Therapeutics Market 2024-2028: Size and High treatment costs; growth driven by the Type, Some of key Companies Positioned Strategically

The sarcoma therapeutics market size by Type (Soft tissue sarcoma and Osteosarcoma) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 1110.8 million. The market is expected to grow at a CAGR of   8.51% between 2024 and 2028.

• The global sarcoma therapeutics market faces significant challenges due to the high cost of treatment for oncology indications. The expense is primarily driven by the complex manufacturing process and substantial research and development costs associated with large molecule drugs, which dominate the market. This high cost can lead to decreased patient adherence to medication, particularly in regions without reimbursement policies or patient assistance programs. The low purchasing power of patients, particularly in Asia and Africa, further exacerbates the issue. The high cost of sarcoma therapeutics is a major concern, as non-adherence to treatment can negatively impact patient outcomes and increase healthcare costs in the long run.
• The sarcoma therapeutics market represents a significant business opportunity for pharmaceutical companies, driven by the high unmet medical need for effective treatments. Sarcomas, a diverse group of malignant tumors, often exhibit aggressive growth and limited treatment options. Market growth is expected due to the pipeline of novel targeted therapies, immunotherapies, and combination treatments. Companies investing in sarcoma therapeutics research and development stand to gain from potential market expansion and improved patient outcomes.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• Adaptimmune Therapeutics plc
• Advenchen Laboratories LLC
• Agenus Inc.
• Agios Inc.
• Athenex Inc.
• Bayer AG
• Bristol Myers Squibb Co.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• Ipsen Pharma
• Johnson and Johnson Services Inc.
• Karyopharm Therapeutics Inc.
• LadRx Corp.
• Mirati Therapeutics Inc.
• Novartis AG
• Pfizer Inc.
• PharmaMar SA
• SillaJen Co. Ltd.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/